Skip to content
lifestyle.brownplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 5, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 13, 2026
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
March 13, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2026
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
March 9, 2026
←
Previous Page
1
2